Scarlet feverA38

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 20.05.2022

Dieser Artikel auf Deutsch

Synonym(s)

Canker rash; Scarlatina; Scarlet fever; Streptococcal sore throat with rash

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Sydenham, 1676

DefinitionThis section has been translated automatically.

Acute streptococcal infection(angina tonsillaris) caused by erythrogenic toxin-forming, beta-hemolytic streptococci of the Lancefield Group A. Obligation to report!

PathogenThis section has been translated automatically.

β-hemolytic Lancefield Group A Streptococci (over 80 different serotypes, type-specific immunity).

EtiopathogenesisThis section has been translated automatically.

Droplet infection. Transmission, also via a contact person or food, is possible. Ports of entry: tonsils, nasopharynx, also wounds.

Streptococcal infections are primarily localized infections. In principle, they do not leave antibacterial immunity. Immunity is produced in scarlet fever only against one of the pyrogenic erythrogenic toxins (there are 4 different toxins that lead to type-specific immunity). This erythrogenic toxin can only be produced if streptococci carry bacteriophages (also called prophages) in their genome that code for it. Specific immunity is directed exclusively against the toxin formed. If an infection by beta-hemolytic streptococci occurs (predominantly angina tonsillaris, only in rare cases by a soft tissue infection = scarlet fever), the classic picture of scarlet fever develops in the absence of immunity against scarlet toxins. If immunity is already present, only streptococcal angina will develop. Since there are several different toxins, multiple scarlet fever reinfections (up to 4) are possible. Erythrogenic toxins belong to the so-called superantigens, which are able to lead to fulminant T-cell proliferation with broad cytokine production without specific antigen processing.

In very rare cases, scarlet fever induced by staphylococcal enterotoxins occurs predominantly in children.

ManifestationThis section has been translated automatically.

Mainly occurring between the ages of 3 and 10.

Clinical featuresThis section has been translated automatically.

  • General: Incubation period 2-5 days.
  • Sudden, highly acute onset with high fever, headache, sore throat, tachycardia, vomiting.
  • Pharyngitis, angina tonsillaris, pressure-dolent cervical lymph node swelling. Less commonly, splenomegaly.
  • Skin lesions (day 2-3): Exanthema, possibly delayed by days. Onset usually in the groin, thigh triangle, or flexor sides of the arms. Furthermore head, neck, trunk, extremities. The face often shows a butterfly-like distributed areal redness. Characteristic is a perioral free zone (facies scarlatinosa).
  • Otherwise, there are pinhead-sized, pale, later red, slightly raised, densely packed papules (see also Miliaria scarlatinosa).
  • Often reduced capillary resistance. The Rumpel-Leede test is positive. In severe course, planar hemorrhages may occur.
  • Mucosal changes (day 3): patchy enanthema on the soft palate. Exfoliation of the tongue coating (thus the entire tongue surface appears homogeneously red, free of coating with swollen lingual papillae = raspberry tongue).
  • Subicterus may be present.
  • Decay phase (day 5-7): Resolution of the now desquamating and pruritic exanthema and angina tonsillaris with lytic temperature reduction. Desquamation: flaky (corneolytic - as after sunburn - scales can be peeled off the skin as a fine translucent membrane) desquamation of the skin on the auricles, face, trunk and extremities. Coarse lamellar desquamation of palmae and plantae.
  • After 2-3 months telogen effluvium, possibly formation of transverse furrows of the nails(Beau-Reilsche transverse furrows) of the nails.

LaboratoryThis section has been translated automatically.

Leukocytosis: 15.000-40.000 leukocytes/μl, later eosinophilia 5-10%.

DiagnosisThis section has been translated automatically.

Clinical, pathogen detection, antistreptolysin titre (AST) increase (at the earliest 8-14 days after a fresh infection, baseline and control values), Dick test, eradication phenomenon.

Differential diagnosisThis section has been translated automatically.

Complication(s)This section has been translated automatically.

Fulminant courses, see below toxic scarlet fever, septic scarlet fever. Otitis, sinusitis, myocarditis, glomerulonephritis, polyarthritis.

TherapyThis section has been translated automatically.

  • Penicillin: Penicillin V (e.g. isocillin) 3 times/day 0,4-1,2 million IU p.o. (infants: 0.2-0.6 million IU/day) over at least 10 days. If reliable intake is not guaranteed, benzathine-penicillin (e.g. tardocillin) once 0.6 million IU or 1.2 million IU i.m. In case of severe course or complications Penicillin G (e.g. Penicillin Grünenthal) 10-20 million IU/day i.v.
  • For penicillin allergy: erythromycin (e.g. erythrocin) 3 times/day 500 mg p.o. (children 40 mg/kg bw/day) or clindamycin (e.g. sobelin) 4 times/day 150-450 mg p.o. Alternatively cephalosporins like cefadroxil (e.g. cedrox) 1 time / day 2 g or cefuroxime (e.g. Elobact) 2 times/day 250 mg p.o. for at least 10 days.

Notice! Co-treatment of other children living in the household is recommended due to possible serious complications (endocarditis, glomerulonephritis, minor chorea, rheumatic fever)!

Progression/forecastThis section has been translated automatically.

Good with early therapy. Letality < 0.5%. Formation of antitoxic antibodies against the specific erythrotoxin in the course of scarlet fever. Also formation of specific antibacterial antibodies.
  • In the presence of a type-specific antibacterial immunity: No clinical disease after streptococcal contact, independent of the presence of antitoxic antibodies.
  • In the absence of type-specific antibacterial immunity and the presence of antitoxic antibodies: Streptococcal pharyngotonsillitis following contact with streptococci.
  • In the absence of the typical specific antibacterial immunity and antitoxic antibodies: angina, streptococcal angina and scarlet fever after streptococcal contact.

LiteratureThis section has been translated automatically.

  1. Hedrick J (2003) Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs 5(Suppl 1): 35-46Mun
    SJ et al (2019) Staphylococcal scarlet fever associated with staphylococcal enterotoxin M in anelderly
    patient. Int J Infect Dis 85:7-9.
  2. Sydenham T (1676) Observationes medicae circa morborum acutorum historiam et curationem. Londini, G. Kettilby, p. 387

Authors

Last updated on: 20.05.2022